Perioperative incidence of ECMO and IABP on 5901 mitral valve surgery procedures

Ignazio Condello1*, Roberto Lorusso2,3, Giuseppe Santarpino1,4,5, Nicola Di Bari6, Flavio Fiore1, Marco Moscarelli1, Antonio Maria Calafiore1, Giuseppe Speziale1 and Giuseppe Nasso1

Abstract

Background: Report the incidence and results of peri-operative extracorporeal membrane oxygenation (ECMO) and intra-aortic balloon pump (IABP) of patients undergoing mitral valve surgery (MVS) through right mini-thoracotomy (RT) and conventional full sternotomy (FS) for a period of 6 years from eleven tertiary Cardiac Surgery Institutes of GVM Care & Research Italia.

Methods: From January 2016 to November 2021, a total of 5901 consecutive patients underwent MVS through RT and FS. The primary outcome of the study was the mortality and incidence of low cardiac output syndrome (LCOS) treated with intra-aortic balloon pump (IABP) with or without inotropic support and the incidence of Postcardiotomy Cardiogenic Shock (PCS) treated with Veno-arterial (VA) Extracorporeal Membrane Oxygenation (ECMO) on patients undergoing mitral valve surgery (MVS) through right mini-thoracotomy (RT) versus conventional full sternotomy (FS).

Results: The mean age was 66 ± 15 years, 3389 patients underwent in RT approach 2512 in FS, 3081 (52%) patients were male and 2.3% had previous cardiac operations. Cardiopulmonary bypass time was 93 min for RT and 81 min for FS and cross clamp time 75 min for RT and 63 min for FS for mitral valve repair. Incidence of perioperative IABP for the treatment of low cardiac output was reported on 99 patients (1.6%), 51 for RT (1.5%), 35% used inotropic support (adrenaline and milrinone) and 48 in FS (1.9), 28% use inotropic support, 21 patients died after IABP (3 RT and 18 FS). Incidence of perioperative VA-ECMO for the PCS treatment was 13 and 4 with IABP, 9 RT (0.2%) and 4 FS approach (0.15%), 12 patients died after VA-ECMO.

Conclusion: Minimally invasive mitral valve surgery is a safe and reproducible approach associated with low mortality and morbidity. ECMO and IABP incidence for the treatment of PCS was 0.2% and for Low cardiac output syndrome (LCOS) was 1.6% in elective mitral valve surgery is very low. The patients that use the perioperative IABP in minimally invasive mitral valve surgery (MIMVS) through RT reported a reduced mortality compared to FS in relation to the operative risk and surgical technique. Low incidence of VA-ECMO was found in RT and FS approach, only one patient survived after VA-ECMO after minimally invasive mitral valve surgery.

Keyword: Extracorporeal membrane oxygenation, Intra-aortic balloon pump, Low cardiac output syndrome, Postcardiotomy cardiogenic shock, Right mini-thoracotomy, Full sternotomy, Mitral valve surgery

Background

Mitrval valve surgery using conventional full sternotomy (FS) is the conventional approach for the treatment of the mitral valve disease. Despite this procedure has shown excellent postoperative outcomes, in the last two decades minimally invasive mitral valve surgery (MIMVS) has gained consensus among surgeons as it has provided
greater patients satisfaction, maintaining the same quality and safety of the standard mitral valve surgery approach [1, 2]. Intra-aortic balloon pump (IABP) is the most usable tool of temporary mechanical circulatory support for cardiac surgical patients suffered from low cardiac output in the early postoperative phase. Its beneficial action is attributed to a concomitant reduction in afterload of left ventricle with a substantial increase on coronary perfusion pressure due to an increase of aortic diastolic pressure. The main indication of IABP use in cardiac surgical patients is peri and post-operatively in the treatment of a low cardiac output state refractory to the usual inotropic support. In literature the 30-day mortality for the patients necessitating IABP is high because of the cardiac problems that led to the need for this pump, ranged from 26 to 50% [3]. Cardiogenic shock, cardiac arrest, acute respiratory failure, or a combination of such events, are all potential complications after cardiac surgery which lead to high mortality [4]. Use of extracorporeal temporary cardio-circulatory and respiratory support for progressive clinical deterioration can facilitate bridging the patient to recovery or to more durable support. Over the last decade, extracorporeal membrane oxygenation (ECMO) has emerged as the preferred temporary artificial support system in such circumstances [5]. Aim of this study was to analyze the incidence and results of perioperative extracorporeal membrane oxygenation (ECMO) and intra-aortic balloon pump (IABP) of patients undergoing mitral valve surgery (MVS) through right mini-thoracotomy (RT) and conventional full sternotomy (FS) for a period of 6 years of eleven Cardiac Surgery Institutes of GVM Care & Research Italia.

Methods

Patient and data collection

A retrospective, observational study was undertaken of prospectively collected data in 5901 consecutive patients undergoing mitral valve surgery, of which 3389 underwent MIMVS through RT between January 2016 to November 2021 for a period of 6 years from 11 Cardiac Surgery Institutes of GVM Care & Research Italia. Two hundred twelve procedures were performed in ten different cardiac surgery institutes of GVM Care & Research Italia. Two hundred twelve procedures were performed under a combination of right mini-thoracotomy and open sternotomy. The primary outcome of the study was the mortality and incidence of low cardiac output treated with intra-aortic balloon pump (IABP) with or without inotropic support and the incidence of Postcardiotomy Cardiogenic Shock (PCS) treated with Veno-arterial (VA) extracorporeal membrane oxygenation (ECMO) on patients undergoing mitral valve surgery (MVS) through right mini-thoracotomy (RT) vs conventional full sternotomy (FS).

Low cardiac output was defined as the need for postoperative inotropic support for more than 48 h in the intensive care unit and/or from an intra-aortic balloon pump.

Surgical technique

The standardized surgical approach for MIMVS has been reported elsewhere. Briefly, MIMVS by a way of right anterior thoracotomy was performed through a 5–7 cm skin incision placed at 3th or 4th intercostal space. Two trocars are inserted in the thorax to allow positioning of a ventricular vent, CO2 insufflator, camera device and pericardial stay sutures. Whereas at the beginning of our experience the approach involved retrograde arterial perfusion and balloon endoclamping, the procedure has evolved to a technique with ascending aorta cannulation, long femoral venous cannula drainage, and direct trans-thoracic aortic clamping. Specifically, direct aortic cannulation was performed using Easyflow (Sorin, Salluggia, Italy) or Straightshot (Edwards Lifesciences, Irvine, Calif) cannulas. Biomedicus single stage (Medtronic, Minneapolis, Minn) or RAP single 2 stage cannulas (Estech) were inserted through the femoral vein into the right atrium and the correct position was achieved with the Seldinger technique under transesophageal echocardiographic guidance. In case of mitral and tricuspid valve surgery, a single 2 stage cannula (RAP, Estech) was used as it allows to drain simultaneously the superior and inferior venae cavae. After vacuum-assisted cardiopulmonary bypass (−40 to −60 mmHg) was established, the patients were cooled to 34 °C. The ascending aorta was clamped with the Cygnet crossclamp (ovare surgical System, Cupertino, Calif) or with the aortic clamp (Cardiomedical GmbH, Langenhagen, Germany; distributed by sorin, Salluggia, Italy) and antegrade cold crystalloid or warm blood cardioplegia is delivered directly into the ascending aorta by a needle vent catheter. For conventional approach on mitral valve surgery was performed in median sternotomy with central cannulation [6].

The mitral valve is approached with a traditional left paraseptal atriotomy and exposed using a specially designed atrial retractor held by a mechanical harm inserted through a right parasternal port. Mitral valve procedures were performed under a combination of direct vision and thorascoscopic assistance. All patients received an accurate intraoperative transesophageal
echocardiogram before and after weaning from cardiopulmonary bypass machine. In patients who had an attempt to repair, our policy is to replace the mitral valve if (a) at the hydrostatic saline test after several attempts, there is still some degrees of mitral regurgitation, (b) the surface of coaptation is not enough to guarantee a long durability, (c) at intraoperative echo, there is more than mild mitral regurgitation. Twelve surgeons contributed to this series, with 2 of them (GS, GN) performing 45.2% of the operations.

**IABP indication and management**

The indications for initiating treatment with IABP in this patients was the following: (a) IABP support for persistent preoperative ischemia despite maximum medical treatment (b) patients not able to be discontinued from CPB although forced inotropic support, (c) patients in low-cardiac output status just after a "difficult" discontinuation of CPB, supported by high-doses of inotropes, (d) patients with "difficult" discontinuation from CPB and spontaneous appearance of arrhythmia (premature ventricular beats or VT) not amenable in antiarrhythmic continuous infusion and (e) post cardiotomy low cardiac output syndrome. Prophylactic initiation of IABP treatment was not advocated in any of the cases [7, 8]. A Datascope system (Datascope Corp, Paramus, NJ) was utilised. The IABP was introduced percutaneously through the common femoral artery in 95 patients and through an open access of the femoral artery in the remaining 4 patients [9]. Correct placement of the device was routinely confirmed with Chest X Ray in ICU. Once mediastinal drainage was minimum (<50 ml/h), patients were anticoagulated with Heparin infusion, keeping the ACT > 180–200 s [10, 11].

**ECMO indication and management**

ECMO was initiated intraoperatively in the operating room for circulatory instability during or immediately after weaning from the cardiopulmonary bypass (CPB) in the primary cardiac procedure. The capability to institute ECMO secondarily in the ICU, for delayed PCS or cardiac arrest, was available. The clinical criteria for PCS included the following: left atrial pressure > 15 mmHg; central venous pressure > 12 mmHg; metabolic acidosis (i.e. pH < 7.3 with serum lactate > 3.0 mmol/L); end-organ hypoperfusion (urine output < 30 mL/h); cardiac index < 2.2L/min/m²; and systolic blood pressure < 80 mmHg despite adequate filling volumes, use of multiple adrenergic agents (epinephrine > 0.1 µg/kg/min or dobutamine > 10 µg/kg/min, norepinephrine > 0.1 µg/kg/min), or an intra-aortic balloon pump (IABP). VA-ECMO support was initiated via peripheral cannulation through the femoral route with the semi-open method, and an additional 6 Fr catheter was systematically inserted distally into the femoral artery to prevent leg ischemia [12]. ECMO blood flow was adjusted on based on clinical assessments (e.g. pre-oxygenator venous oxygen saturation, evidence of hyperperfusion, resolution of hyperlactatemia, normalization of mean arterial pressure). Intravenous unfractionated heparin was given to maintain an activated clotting time of 180–210 s, or an activated partial thromboplastin time of 1.5–2 times normal. ECMO-related complications were carefully monitored. ECMO weaning was performed in patients who fulfilled our published institutional weaning criteria and passed an ECMO weaning trial consisting in decreasing and clamping ECMO flow. In general, the patient should have a pulsatile arterial waveform for at least 24 h; be hemodynamically stable, with baseline mean arterial pressure greater than 60 mmHg with no or low doses of catecholamines; should have left ventricular ejection fraction (LVEF) of 35%, and an aortic velocity time integral (VTI) of ≥ 12 cm; and have recovered from major metabolic disturbances [13]. Weaning was considered unsuccessful if ECMO re-cannulation was required within 2 days of decannulation.

**Statistical analysis**

Continuous data were expressed as mean ± standard deviation or median with the interquartile range and categorical data as percentages. All statistical analyses were performed with SPSS 22.0 (SPSS, Inc., Chicago, IL, USA).

**Results**

The mean age was 66 ± 15 years, 3389 patients underwent in RT approach 2512 in FS, 3081 (52%) patients were male and 2.3 had previous cardiac operations, the patient characteristics were reported in (Table 1).

Cardiopulmonary bypass time was, 93 min for RT vs 81 min for FS and cross clamp time, 75 min for RT vs 63 min for FS for mitral valve repair (Table 2). The most predominant pathology was degenerative disease, followed by functional mitral valve regurgitation rheumatic disease, endocarditis and prosthetic dysfunction (Tables 3, 4). Mitral valve repair was performed in 3207 patients 78% in RT and 2694 had mitral valve replacement 58% in RT. Direct aortic cannulation was achieved in 825 patients. Repair techniques included annuloplasty, leaflet resection, neochordae implantation and sliding plasty (11%). Concomitant procedures included tricuspid valve repair (14.6%), atrial fibrillation ablation (9.5%) and atrial septal defect closure (3.2%). Overall in-hospital mortality was 1.1%. 78 had conversion to sternotomy. Incidence of perioperative IABP for the treatment of LCOS was reported on 99 patients (1.6%), 51 (1.5%) for RT; 35% used inotropic
support (adrenaline and milrinone) and 48 in FS (1.9%), 28% use inotropic support, 21 patients died after IABP (3 RT vs 18 FS) (Tables 5, 6). Incidence of perioperative VA-ECMO for the PCS treatment was 13 (0.2%) and 4 with IABP, (9 RT vs 4 FS approach), 12 patients died after VA-ECMO (Table 7).

**Discussion**

Despite this study reports a good result for mitral valve surgery both in FS and MIMVS, the perioperative LCOS the most serious complication and is associated with increased morbidity, short- and long-term mortality, and healthcare resource utilization.
The presented analysis represents a pilot of our experience. Due to these preliminary results we are going to prepare a statistical analysis with a comparison between two comparable groups and multivariate. This syndrome is characterized by decreased heart pump function, leading to reduced oxygen delivery (DO2) and subsequent tissue hypoxia. The most common definition of LCOS also includes decreases in the cardiac index (CI) to < 2.0 L/min/m² and a systolic blood pressure of <90 mmHg, in conjunction with signs of tissue hypoperfusion (cold periphery, clammy skin, confusion, oliguria, elevated lactate level) in the absence of hypovolemia. The use of inotropic agents or mechanical circulatory support always is required to improve patient hemodynamics. Although studies have reported that the occurrence of LCOS may be related to preoperative cardiac function, intraoperative operations and CPB, there are still no exact indicators to reflect the risk of its occurrence. At present, domestic and foreign studies on the risk factors of LCOS are inconsistent [14]. It is believed that the occurrence of LCOS is caused by multiple factors, including impaired systolic and diastolic function of the heart, changes in cardiac load, and activation of inflammatory transmitters [15]. The patients that use the perioperative IABP in minimally invasive mitral valve surgery (MIMVS) through RT report a reduced mortality compared to FS in relation to the operative risk and surgical technique, this could be related to the elimination of sternotomy, which reduces

| Table 3 Mitral valve pathology for minimally invasive mitral valve surgery |
|---------------------------------------------------------------|
| Mitral valve pathology | Right-thoracotomy N = 3389 | Repair N = 2898 | Replacement N = 491 |
|------------------------|-----------------------------|-----------------|---------------------|
| Degenerative           | 2739 (80.8%)                | 2540 (87.6%)    | 199 (40.5%)         |
| Functional             | 328 (9.6%)                  | 231 (7.9%)      | 97 (19.7%)          |
| Reumathic              | 247 (7.2%)                  | 97 (3.3%)       | 150 (30.5%)         |
| Endocarditis           | 28 (0.8%)                   | 3 (1.0%)        | 25 (5.0%)           |
| Prosthesis dysfunction | 19 (0.5%)                   | 1 (0.03%)       | 18 (3.6%)           |
| Miscellaneous          | 28 (0.9%)                   | 26 (0.9%)       | 2 (0.4%)            |

| Table 4 Mitral valve pathology for full sternotomy mitral valve surgery |
|---------------------------------------------------------------|
| Mitral valve pathology | Full Sternotomy N = 2512 | Repair N = 1999 | Replacement N = 513 |
|------------------------|-----------------------------|-----------------|---------------------|
| Degenerative           | 1781 (70.8%)                | 1639 (81.9%)    | 142 (27.6%)         |
| Functional             | 367 (14.6%)                 | 179 (8.9%)      | 188 (36.6%)         |
| Reumathic              | 289 (11.5%)                 | 143 (6.6%)      | 146 (28.4%)         |
| Endocarditis           | 29 (1.1%)                   | 7 (0.3%)        | 22 (4.2%)           |
| Prosthesis dysfunction | 17 (0.67%)                  | 10 (0.5%)       | 17 (1.36%)          |
| Miscellaneous          | 29 (1.15%)                  | 21 (1.0%)       | 8 (1.5%)            |

| Table 5 Perioperative incidence of IABP for Mitral valve pathology in Full Sternotomy (FS) |
|-----------------------------------------------|
| IABP                           | FS N = 48 | Repair N = 26 | Replacement N = 22 | Inotropic support 28% | Death 30 days 18 |
|-------------------------------|-----------|---------------|---------------------|-----------------------|-----------------|
| Degenerative                  | 15        | 1             |                     |                       |
| Functional                    |           | 11            |                     |                       |
| Reumathic                     |           | 4             |                     |                       |
| Endocarditis                  | 5         | 3             |                     |                       |
| Prosthesis dysfunction        | 6         | 3             |                     |                       |
| Miscellaneous                 |           |               |                     |                       |

IABP, intra-aortic balloon pump; FS: full sternotomy

| Table 6 Perioperative incidence of IABP for mitral valve pathology in MIMVS |
|-----------------------------------------------|
| IABP                           | RT N = 51 | Repair N = 22 | Replacement N = 29 | Inotropic support 35% | Death 30 days 3 |
|-------------------------------|-----------|---------------|---------------------|-----------------------|-----------------|
| Degenerative                  |           |               |                     |                       |
| Functional                    |           | 13            | 18                  |                       |
| Reumathic                     |           | 4             | 1                   |                       |
| Endocarditis                  |           | 5             | 9                   |                       |
| Prosthesis dysfunction        |           |               |                     |                       |
| Miscellaneous                 |           |               |                     |                       |

IABP, intra-aortic balloon pump; MIMVS, minimally invasive mitral valve surgery; RT, right thoracotomy
the time of mechanical ventilation and the postoperative recovery time [6].

Postcardiotomy cardiogenic shock (PCS), defined as low cardiac output syndrome with evidence of tissue hypoperfusion and end-organ dysfunction despite adequate preload, affects 0.2% to 6% of patients who undergo cardiothoracic surgery [15]. PCS is a life-threatening complication with mortality rates between 50 and 80% and includes the inability to wean from cardiopulmonary bypass (CPB) in the operating room or deterioration of myocardial function during the first postoperative days. Between 70 and 90% of the patients who cannot be easily separated from CPB because of PCS can be weaned from CPB by support of inotropes, vasopressors, and intra-aortic balloon pumps, and an estimated two thirds of these patients will recover hemodynamically without the need for other mechanical circulatory support. In comparison, PCS refractory to intravascular volume loading, pharmacologic, and intra-aortic balloon pump support occurs postoperatively in 0.5–1.5% of patients and will inexorably lead to death unless more efficient circulatory support is initiated [16]. The main limitation of this study is its retrospective nature; however our database is prospectively compiled. Although we reported the incidence of LOCS and PCS results, echocardiographic data were not available for all patients. No information has been recorded regarding the aetiology of perioperative myocardial infarction as well as no information has been reported regarding the cause of late mortality. Nevertheless a well-designed study with appropriate sample size is required to validate this results.

Conclusion
ECMO and IABP incidence for the treatment of PCS was 0.2% and for Low cardiac output syndrome (LCOS) was 1.6% in elective mitral valve surgery is very low in right mini-thoracotomy (RT) and conventional full sternotomy (FS). The patients that use the peroperative IABP in minimally invasive mitral valve surgery (MIMVS) through RT reported a reduced mortality compared to FS in relation to the operative risk and surgical technique. Only one patient survived after VA-ECMO after minimally invasive.

Table 7 Perioperative incidence and mortality of ECMO in FS and RT approach

|       | VA-ECMO | IABP | Inotropic support | Survival |
|-------|---------|------|-------------------|----------|
| FS    | 4       | 1    |                   |          |
| RT    | 9       | 3    |                   | 1        |
| Tot   | 13      | 4    |                   | 53%      |

IABP, intra-aortic balloon pump; RT, right thoracotomy; FS, full sternotomy; VA-ECMO, Veno-arterial extracorporeal membrane oxygenation

Abbreviations
MIMVS: Minimally invasive mitral valve surgery; FS: Full sternotomy; RT: Right thoracotomy; MVS: Mitral valve surgery; IABP: Intra-aortic balloon pump; VA-ECMO: Veno-arterial extracorporeal membrane oxygenation; LCOS: Low cardiac output syndrome; PCS: Post cardiomyocyte shock

Acknowledgements
None.

Authors’ contributions
IC participated in manuscript writing, revision and conception. RL participated in conception and manuscript vision. GS and ND participated in support and conception. FF and MM participated in support, re-writing and revision. AC and GSP participated in support and conception. GN participated in conception and manuscript vision. All authors read and approved the final manuscript.

Funding
None.

Availability of data and materials
The datasets used and analysed during the current study are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
The study was evaluated and approved by the institutional board for clinical trials, Anthea Hospital GVM Care&Research and Informed consent was obtained from all subjects involved in the study.

Consent for publication
All authors have read and agreed to the published version of the manuscript.

Competing interests
The authors declare no competing interests.

Author details
1 Department of Cardiac Surgery, Perfusion Service, Anthea Hospital, GVM Care and Research, Via Camillo Rosalba 35/37, 70124 Bari, Italy. 2 Cardio-Thoracic Surgery Department, Heart and Vascular Centre, Maastricht University Medical Centre, Maastricht, The Netherlands. 3 Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands. 4 Department of Cardiology, Paracelsus Medical University, Nuremberg, Germany. 5 Department of Cardiac Surgery, Department of Experimental and Clinical Medicine, "Magna Graecia" University of Catanzaro, Catanzaro, Italy. 6 Division of Cardiac Surgery, Dipartimento Di Emergenza E Trapianti Di Organo (D.E.T.O.), University of Bari, Bari, Italy.

Received: 4 January 2022 Accepted: 12 March 2022

Published online: 17 March 2022

References
1. Glauber M, Miceli A, Canarutto D, et al. Early and long-term outcomes of minimally invasive mitral valve surgery through right mini-thoracotomy: a 10-year experience in 1604 patients. J Cardiothorac Surg. 2015;10:181. https://doi.org/10.1186/s13019-015-0390-y.
2. McClure RS, Athanasopoulos LV, McGurk S, Davison MJ, Couper GS, Cohn LH. One thousand minimally invasive mitral valve operations: early outcomes, late outcomes, and echocardiographic follow-up. J Thorac Cardiovasc Surg. 2013;145:1199–206.
3. Parissis H, Leotsinidis M, Akbar MT, et al. The need for intra aortic balloon pump support following open heart surgery: risk analysis and outcome. J Cardiothorac Surg. 2010;5:20. https://doi.org/10.1186/1749-8090-5-20.

4. Bellumkonda GB, Masri SC. Evolving concepts in diagnosis and management of cardiogenic shock. Am J Cardiol. 2018;122:1104–10.

5. Fux T, Holm M, Corbascio M, Lund LH, van der Linden J. Venoarterial extracorporeal membrane oxygenation for postcardiotomy shock: risk factors for mortality. J Thorac Cardiovasc Surg. 2018;156:1894–902.

6. Glauber M, Karimov JH, Farneti PA, Cerillo AG, Santarelli F, Ferrarini M, et al. Minimally invasive mitral valve surgery via right minithoracotomy. Multimed Man Cardiothorac Surg. 2009. https://doi.org/10.1510/mmcts.2008.003530.

7. Kantrowitz A. Origins of intra-aortic balloon pumping. Ann Thorac Surg. 1990;50:672–4.

8. MacGee, E., MacCarthy, P., & Moazami, N. Temporary mechanical circulatory support. In Cohn, L. (Ed.) Cardiac Surgery in the Adult, MacGraw Hill, New York, 507–33 (2008).

9. Katz E, Tunick P, Kronzon I. Observations of coronary flow augmentation and balloon function during intraaortic balloon caunterpulsation using transesophageal echocardiography. Am J Cardiol. 1992;69:1635–9. https://doi.org/10.1016/0002-9149(92)90716-C.

10. Tedoriya T, Akemoto K, Imai T. The effects of blood flows of coronary artery bypass grafts during intra-aortic balloon pumping. J Cardiovasc Surg. 1994;35:99–102.

11. Christenson J, Cohen M, Ferguson J, Freedman R, Miller M, Ohman E, Reddy R, Stone G, Urban P. Trends in intraaortic balloon counterpulsation complications and outcomes in cardiac surgery. Ann Thorac Surg. 2002;74:1086–90. https://doi.org/10.1016/S0003-4975(02)03854-7.

12. Magovern GJ, Magovern JA, Benckart DH, et al. Extracorporeal membrane oxygenation: preliminary results in patients with postcardiotomy cardiogenic shock. Ann Thorac Surg. 1994;57:1462–8.

13. Lorusso R, Raffa GM, Alenizy K, et al. Structured review of post-cardiotomy extracorporeal membrane oxygenation: part 1—adult patients. J Heart Lung Transplant. 2019;38(11):1125–43. https://doi.org/10.1016/j.healun.2019.08.014.

14. Maganti MD, Rao V, Borger MA, Ivanov J, David TE. Predictors of low cardiac output syndrome after isolated aortic valve surgery. Circulation. 2005;112(suppl.1):I448–52.

15. Rao V, Ivanov J, Weisel RD, Ikonomidou JS, Christakis GT, David TE. Predictors of low cardiac output syndrome after coronary artery bypass. J Thorac Cardiovasc Surg. 1996;112:38–51.

16. Slottosch I, et al. Outcomes after peripheral extracorporeal membrane oxygenation therapy for postcardiotomy cardiogenic shock: a single-center experience. J Surg Res. 2013;181:47–55.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.